Xenetic Biosciences Headquarters Grand Opening in Lexington, MA

Lexington, MA – On Tuesday March 4th, Xenetic

Biosciences (OTCBB: XBIO) will host a grand opening and ribbon cutting ceremony,
followed by a lunch reception, to celebrate the completion of the company’s
relocation of its global headquarters to Lexington, MA from London, UK. Xenetic is a biopharmaceutical company
developing next-generation biologic drugs and novel oncology therapeutics with a
focus on rare and orphan diseases.

Scott Maguire, Xenetic
Biosciences Chief Executive Officer, will speak, along with Massachusetts Life
Sciences Center President & CEO Susan Windham-Bannister, Ph.D., Peter Abair
of MassBio, Massachusetts State Representative Jay Kaufman and Lexington Town
Manager Karl Valente, followed by a ceremonial ribbon cutting, and lunch
reception featuring tours of the new facility. The event will take place at 99
Hayden Road, East Wing Lobby, Lexington, MA at 11:00 a.m. EST.

About Xenetics Biosciences

Xenetic Biosciences Inc. (OTCBB: XBIO) is a biopharmaceutical
company developing next-generation biologic drugs and novel oncology
therapeutics. Xenetic's proprietary drug technology platforms include PolyXen®
for creating next generation biologic drugs by extending the efficacy, safety
and half-life of biologic drugs and OncoHist® for the development of novel
oncology drugs focused on orphan indications. Xenetic's lead product candidates
include ErepoXen®, an improved, polysialylated form of erythropoietin (EPO) for

the treatment of anemia in pre-dialysis patients with chronic kidney disease

and OncoHist®, a recombinant human histone H1.3 molecule which Xenetic is

developing for the treatment of refractory Acute Myeloid Leukemia (AML).


Xenetic is developing a novel series of polysialylated blood coagulation

factors through its license agreement with Baxter International Inc. Xenetic is

also developing a broad pipeline of clinical candidates for next generation

biologics and novel oncology therapeutics in a number of orphan disease

indications. For more information, please visit the Company's website at www.xeneticbio.com.